New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.
Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.
A clinical trial in Australia offers $20,000 for participation, aiming to regrow hair and reverse grey hair. Participants must not have used hair treatments recently and must visit a Melbourne clinic regularly over 18 months.
The conversation humorously discusses the unfairness of hair loss, highlighting various treatments like finasteride, minoxidil, red light therapy, and experimental drugs, while contrasting with people who have great hair despite unhealthy lifestyles. The original poster mentions experiencing side effects from switching to oral finasteride.
User reports 2-month progress using Fin, Min, and microneedling for hair regrowth. Mixed opinions on results, some skeptical of fast growth, others encouraging and recommending Fin for stable results.
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
The conversation is about hair loss treatments, specifically mentioning finasteride, minoxidil, and the possibility of a hair transplant in Turkey. Users share humorous reactions and personal experiences with these treatments.
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
The conversation is about a meme related to hair loss that influenced someone to start taking finasteride. Another person agrees that the meme accurately represents the situation.
The conversation is about a hair transplant operation video by a clinic owner, with comments suggesting it's staged for marketing and criticizing the unrealistic hairline created. Some users question the necessity of the transplant for the individual featured.
A 27-year-old male experienced significant hair regrowth in two months using a daily oral 3-in-1 pill containing 1.1mg finasteride, 5mg minoxidil, and 1mg biotin from LockLab, with no side effects reported. The user also uses a derma-stamp twice a week to promote blood flow and stimulate growth.
A user switched from finasteride to Avodart (dutasteride) due to the ineffectiveness and poor quality of finasteride in their country. They advise others in similar situations to seek original brands.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
The conversation is about finding a place to buy 0.025% topical finasteride in liposomal gel form in Europe. The user previously mixed their own with stemoxydine but stopped due to an oily scalp.
A user shared their positive experience with a no shave FUE hair transplant by Dr. Ko in Seoul, including aftercare with oxygen therapy, red light therapy, and prescribed dutasteride and oral minoxidil (2.5mg daily). The procedure cost over $5,000 USD, and the user is satisfied with the results.
A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.
The user discusses using Follics FR5, FR10, and FR15, which combine Minoxidil, Adenosine, Procapil, Azelaic acid, and Procyanidin B2, to address hair loss. They have previously used Minoxidil, Finasteride, and Dutasteride with varying success.
A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.
The user regrets not using medication after a failed hair transplant and is now using a combination of minoxidil, finasteride, derma rolling, oils, and ketoconazole shampoo to try to improve hair regrowth. They are seeking feedback on progress and considering further treatment options.
The conversation is about hair loss and the effectiveness of treatments like finasteride, with one user expressing satisfaction after seeing hair regrowth on CCTV. Other users share their experiences with hair visibility and discuss the effectiveness of finasteride compared to dutasteride.
The conversation is about a person considering participating in a study for Clascoterone, a topical cream for hair loss, and seeking advice on potential side effects. They have mild hair loss and are not currently using other treatments like finasteride.
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.
The conversation discusses a video about hair shedding related to finasteride and dutasteride, with some users debating the credibility of non-professional sources. The video is praised for compiling work by doctors and researchers, despite some users preferring content from licensed medical professionals.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
DIM is suggested to help with estrogen metabolism for those on finasteride or dutasteride, potentially reversing side effects like fat gain and mood changes. Some users doubt its effectiveness, recommending lifestyle changes or consulting a doctor instead.